Army Department September 7, 2010 – Federal Register Recent Federal Regulation Documents

In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive, revocable license for the field of use in the research reagent market to the invention described in U.S. Patent Application No. 61/252,675 entitled ``Enhanced Substrates for The Protease Activity of Serotype A Botulinum Neurotoxin,'' filed October 18, 2009, to List Biological Laboratories, with its principal place of business at 540 Division Street, Campbell, California 95008-6906.